coformulation favezelimab/pembrolizumab

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)Small Cell Lung Carcinoma

Phase 1

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

RecruitingNCT04938817

Merck Sharp & Dohme LLCSmall Cell Lung Carcinoma

Start: 2021-08-19End: 2029-12-10Target: 110Updated: 2026-03-19

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

CompletedNCT05342636

Merck Sharp & Dohme LLCEsophageal Squamous Cell Carcinoma (ESCC)

Start: 2022-07-27End: 2025-12-05Updated: 2025-12-17

Related Papers

Abstract CT256: Results from KEYNOTE-B98: A phase 1b/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer (ES-SCLC)

Cancer Research2024-04-052 citations

KEYMAKER-U06 substudy 06A trial in progress: A phase 1/2 study of investigational agents with pembrolizumab (pembro) plus chemotherapy (chemo) or lenvatinib in PD-1/L1 treatment-naïve advanced esophageal cancer.

Journal of Clinical Oncology2023-01-24